Home > Newsletters > FDAnews Drug Daily Bulletin > J&J Discloses New Investigations, Risperdal Agreement
FDAnews Drug Daily Bulletin
Aug. 16, 2012 | Vol. 9 No. 161
J&J Discloses New Investigations, Risperdal Agreement
Johnson & Johnson (J&J) is facing two new federal investigations into its marketing practices for a drug and a device, just as it is hammering out a settlement over off-label allegations for its antipsychotic Risperdal. J&J subsidiary Janssen Pharmaceuticals is responding to the new Department of Justice request for documents on antibiotic Doribax (doripenem), according to an SEC filing. The company stopped trials on the drug in January after significant safety concerns surfaced.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.